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Abstract 
 
Saponins are a broad class of functionally diverse phytochemicals that have been 
shown to exhibit antihyperglycemic, antihyperlipidemic, anti-inflammatory, and anti-
cancer effects. Through in vitro and in vivo experimentation, Astragaloside IV (AsIV) has 
been shown to regulate glycogen synthesis through protein kinase B (AKT)-mediated 
phosphorylation of glycogen synthase kinase 3-beta (GSK-3β). Along with control of 
glucose homeostasis, AKT activation is also an important regulator of protein synthesis via 
the downstream phosphorylation of mammalian target of rapamycin (mTOR) and 
ribosomal protein S6 kinase beta-1 (S6K1). Because AsIV can activate this pathway to 
stimulate glucose metabolism, it is possible that it can also promote protein synthesis as 
well since these two regulatory processes utilize the same pathway. In order to determine 
the effect of AsIV on protein synthetic pathways, C2C12 murine muscle cells were treated 
with AsIV and the phosphorylation levels of key enzymes were assessed.  
We found that AsIV induced phosphorylation of key protein synthetic targets in a 
time-dependent manner, with the greatest increases in phosphorylation after two hours of 
AsIV treatment. However, this effect was not seen when cells were serum-starved prior to 
AsIV treatment. Lastly, AsIV was able to increase GSK-3β phosphorylation in cells treated 
with dexamethasone first. These findings help to further understand the molecular changes 
that occur in muscle cells treated with AsIV. 
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1 
Introduction 
Atrophy of skeletal muscle is a serious consequence of many conditions, such as 
COPD, HIV/AIDS, chronic kidney and heart diseases, cancer, and diabetes (Schiaffino 
and Mammucari 2011). There is an association between Cachexia, the involuntary body 
wasting caused by chronic disease states, and poorer outcomes from these chronic 
diseases (Evans et al. 2008). As such, it poses a major public health issue (Farkas et al. 
2013). While the specific mortality rates vary with each different disease, from 10-15% 
in COPD, to 60-80% in cancer patients (Farkas et al. 2013), cachexia occurs in 30% of 
patients who die from these diseases overall (von Haehling and Anker 2010). Within the 
industrialized nations of North American, Europe, and Japan, the prevalence of cachexia 
is estimated to be around 1% of the populations, or nine million people (von Haehling 
and Anker 2010).  
Maintaining healthy muscle mass is a balance between control of synthesis and 
degradation. While there is currently no single, established pathway by which body 
wasting occurs, the regulation of protein synthesis may play an important role. There 
appears to be an “anabolic-catabolic dysbalance” seen with cachexia, as a result of 
dysfunction to multiple body systems (von Haehling and Anker 2010). In patients with 
cancer or COPD cachexia, a reduction in muscle protein synthesis was an important 
factor (Morrison et al. 1988), while increased muscle breakdown was also present in 
cardiac cachexia (von Haehling and Anker 2010).  
There are currently no medical interventions to treat muscle atrophy, only 
strategies to help reverse it by either blocking the activation of pathways that lead to 
protein degradation and atrophy, or stimulate the pathways that lead to protein synthesis 
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and muscle hypertrophy (Glass 2003). However, this is easier said than done due to the 
necessity of both growth and degradation for proper muscle homeostasis. Therefore, it is 
important to understand the molecular mechanisms behind these signaling pathways 
(Sitnick 2006) and to identify ways to reverse muscle wasting via these pathways. 
Regulation of protein synthesis via Akt 
The regulation of muscle mass requires a constant equilibrium between protein 
synthesis and breakdown, and studies have shown that the Akt/mammaliam target of 
rapamycin (mTOR) signaling pathway is the mechanism controlling this balance (Glass 
2003). The pathway is stimulated by extracellular insulin, insulin-like growth factor 1 
(IGF1), or other structural analogs that are capable of binding to and activating receptors 
on the cell membrane. The IGF1-Akt1 and insulin-Akt2 pathways are interconnected and 
share many of the same components. In addition, IGF1 is capable of binding to the 
insulin receptor and insulin is capable of binding to the IGF1 receptor (Schiaffino and 
Mammucari 2011). However, different ligands can lead to slightly different downstream 
effects as IGF1 is more involved with muscle growth and insulin is more active in 
glucose metabolism (Schiaffino and Mammucari 2011). 
IGF binding to the IGF1 receptor (IGFR) leads to downstream activation of Akt, 
which leads to increased protein synthesis, decreased protein degradation, and increased 
glucose metabolism and transport (Figure 1). When IGF1 binds to its receptor, it leads to 
autophosphorylation of the receptor via activation of its intrinsic tyrosine kinase activity. 
This creates a docking site for insulin receptor substrate (IRS), which is then 
phosphorylated by the IGF1 receptor as well. Phosphorylated IRS then activates 
phosphatidylinositol-3-kinase (PI3K), which converts phosphoinositide-4,5-biphosphate 
3 
(PIP2) into phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 acts a docking site for 
phosphoinositide-dependant kinase 1 (PDK-1) and Akt, allowing for PDK-1 to activate 
Akt by phosphorylating it at threonine 308. These actions all occur at the inner surface of 
the cell membrane. 
 
 
 
Figure 1: Overview of the IGF1/Akt pathway. This pathway controls protein synthesis, degradation and 
glucose metabolism and transport via activation of downstream target proteins. Arrows designate one 
protein activating another, red lines with a perpendicular red line at the end designates one protein 
inhibiting another. Modified from Sartorelli V and Fulco M. Sci. STKE 244:1-7 (2004). 
Akt then increases the rate of protein synthesis via two related mechanisms. First, 
Akt indirectly activates mTOR signaling, which includes two complexes: mTORC1 and 
mTORC2. mTORC2 is important for Akt activation via positive feedback that 
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phosphorylates Akt at serine 473, which is necessary for optimal activation of Akt. 
mTORC1 is bound to Raptor and phosphorylates ribosomal protein S6 kinase beta-1 
(S6K1), which promotes protein translation efficiency. mTORC1 also increases protein 
synthesis via phosphorylation and subsequent inhibition of eukaryotic translation 
initiation factor 4E-binding proteins (4EBP1). Inactivation of these binding proteins 
blocks the inhibition of translation initiation factor 4E, allowing for the assembly of the 
ribosomal complex and translation initiation.  
Second, Akt promotes protein synthesis via phosphorylation and inhibition of 
glycogen synthase kinase 3 beta (GSK-3β). This protein inhibits another translation 
factor: eukaryotic translation initiation factor 2B, which is important for the formation of 
the initial tertiary complex of mRNA and the ribosomal subunits, allowing for the 
binding of the tRNAiMet to the ribosome. Therefore, inhibition of GSK-3β by mTORC1 
also leads to increased protein translation. 
Akt also regulates protein metabolism by decreasing the rate of protein 
degradation. This is achieved via phosphorylation and inhibition of the forkhead box O 
(FoxO) family of transcription factors. Specifically, FoxO3 acts on both the proteasomal 
and autophagic-lysosomal pathways to induce protein degradation (Schiaffino and 
Mammucari 2011). First, FoxO3 regulates the transcription of ubiquitin ligases muscle 
atrophy F-box (MAFbx) and muscle ring finger 1 (MuRF1), which cause ubiquitylation 
of myosin and other muscle proteins, marking them for degradation by the proteasome 
(Lecker et al. 2006). Second, FoxO3 also regulates the transcription of proteins needed to 
activate the autophagy-lysosome pathway. Normal autophagic activity is necessary for 
removing dysfunctional organelles and preserving the integrity of muscle fibers. The net 
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effect of Fox03 activation is an increase in muscle atrophy, which is inhibited by IGF1-
mediated Akt activation (Sandri 2011). 
Significance for control of muscle growth and loss 
 Genetic knockout studies have provided insight into the importance of the 
IGF/Akt pathway on muscle metabolism. Mice lacking the IGF1 gene, igf1, had severe 
growth retardation with most mice dying shortly after birth (Lui et al. 1993). In addition, 
mice possessing a mutated, inactive IGF receptor controlled by a muscle-specific 
promoter had delayed growth up to three weeks of age (Fernandez et al. 2002) and 
impairment of muscle regeneration in adulthood (Heron-Milhavet et al. 2010). Deletion 
of the akt1gene in mice led to growth retardation (Chen et al. 2001; Cho et al. 2001a), 
while akt2 deletion caused deficits in glucose metabolism without affecting growth (Cho 
et al. 2001b). When both genes were knocked out, there was significant growth 
retardation and atrophy of skeletal muscle (Peng et al. 2003). Additionally, in vivo studies 
have confirmed that this pathway is suppressed in mouse models of muscle atrophy 
(Sitnick 2006; 2009) 
 In comparison, activation or over-expression of this pathway can lead to muscle 
growth. First, Coleman et al. (1995) used the avian skeletal α-actin gene to create a 
myogenic expression vector to direct the expression of IGF1 cDNA in skeletal muscle. 
This resulted in localized over-expression of IGF1 in skeletal muscle and resulted in 
striated muscle hypertrophy. Second, Lai et al. (2004) transfected mice embryos with an 
Akt cDNA vector controlled by the human skeletal actin promoter, creating transgenic 
mice with constitutively active Akt expressed in their skeletal muscle. Again, this 
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transgenic model led to increased hypertrophy of muscle fibers, as well as increased 
activation of the downstream protein target S6K1.  
These studies highlight the importance of these proteins in maintaining muscle 
mass, and provide evidence that increased activation of the IGF1/Akt pathway can 
promote protein synthesis and muscle hypertrophy. Akt is not only involved in protein 
synthesis, however, it is also the pathway controlling glucose metabolism and transport. 
Regulation of glucose metabolism and transport via Akt 
The PI3K/Akt pathway is a highly conserved cell-signaling pathway that 
facilitates glucose uptake and metabolism. It is initiated primarily by insulin and is 
especially important for insulin-dependent cells like muscle, but may also be activated by 
other extracellular growth factors like IGF1 (Ward and Thompson 2012; Schiaffino and 
Mammucari 2011). The initial steps in this pathway are similar to those that affect protein 
synthesis (see Figure 1). Extracellular growth factors bind to their cell membrane 
receptors and lead to activation of PI3K. This enzyme then phosphorylates 
phosphatidylinositol lipids, which eventually leads to phosphorylation and activation of 
Akt. 
Akt increases glucose uptake by increasing the expression of glucose transporters 
(GLUT) at the cell surface. Class I facilitative glucose transporters are divided into four 
isoforms: GLUT1 – GLUT4. The insulin-responsive GLUT4 is the predominant type 
found at the cell surface of skeletal muscle (Navale and Paranjape 2016). In non-
stumulated cells, GLUT4 is found mostly on the interior of the cell within cytoplasmic 
vesicles. Akt phosphorylates AS160 (Akt substrate of 160 kDa), which inhibits it and 
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causes increased exocytosis and deceased endocytosis of GLUT4 (Swiderska et al. 2018). 
The net effect is increased GLUT4 transporters at the cell surface. 
Akt also activates enzymes necessary for glycolysis and glycogenesis. First, Akt 
increases hexokinase activity by promoting its association with mitochondria (Gottlob et 
al. 2001). Hexokinase catalyzes the first reaction of glycolysis, converting glucose to 
glucose 6-phosphate. Second, Akt phosphorylates and inhibits GSK-3β just like it does in 
the protein synthesis pathway. In the synthesis of glycogen, GSK-3β phosphorylates and 
inhibits glycogen synthase (GS). GS is a key enzyme in glycogen formation; it catalyzes 
the incorporation of glucose into the glycogen chain via a α(1→4) glycosidic bond. 
When active, GSK-3β inhibits glycogenesis by inhibiting GS. However, Akt inhibits 
GSK-3β, so the net effect of Akt activation is an overall increase in glycogen synthesis. 
It is clear that both glucose metabolism and protein synthesis share the same 
upstream pathway of PI3K/Akt phosphorylation. If a compound or chemical is capable of 
stimulating this pathway to improve glucose metabolism and transport, it is theoretically 
possible for such a compound to stimulate this pathway to improve protein synthesis. If 
so, this mechanism may represent a therapeutic target for treating muscle wasting caused 
by various medical conditions and aging. Therefore, it is important to identify substances 
that may in this manner. A group of compounds that may potentially elicit this effect are 
called saponins. 
Saponins overview 
 Saponins are a class of naturally occurring phytochemicals that are widely 
distributed among various plant species. They are glycosides containing one or more 
sugar chains attached at varying locations to an aglycone backbone. They can be broadly 
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classified as either triterpenoid (Figure 2A) or steroidal (Figure 2B) based on the 
structure of their aglycone backbone, called a sapogenin Both backbone types are derived 
from the same 30-carbon linear precursor (Moses et al. 2014), but subsequent processing 
creates one of the two backbone subtypes. Steroidal sapogenins (27C) may possess as 6-
ring spirostane or 5-ring furostane skeletons. The triterpenoid sapogenins contain four or 
five ring backbones and are more structurally diverse (Podolak et al. 2010). 
Saponins can be further classified as mono, di-, or tridesmosidic based on the 
number of sugar chains they possess (Güçlü-Ustündağ and Mazza 2007). The 
combination of the lipid-soluble backbone and water-soluble sugar residues makes 
saponins generally amphipatic with emulsifying and foaming properties (Wang et al. 
2005). However, the complexity and structural diversity of these compounds leads to a 
number of other biological effects that vary from one saponin to the next, some of which 
are not completely understood (Moses et al. 2014). 
A: 
 
 
 
 
 
 
B: 
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Figure 2: Structural difference between steroidal and triterpenoid saponins. Structure of the triterpene 
aglycone backbone (A), containing 30 carbons, compared to the steroid aglycone (B) containing 27 
carbons. In either case, the backbone is called a sapogenin. The addition of one or more sugar chains makes 
the molecule a saponin. Modified from Güçlü-Ustündağ and Mazza 2007.  
 Several studies have attempted to correlate biological activity with the structural 
variations between different saponins (Francis et al. 2002). Collectively, saponins are 
commonly researched for their cytotoxic, lipid-lowering, anti-inflammatory, and immune 
system effects. Most importantly for our study, however, is the effects that saponin have 
been shown to exert in glucose metabolism and transport. Matsuda et al. (1999) found 
various oleanolic acid oligoglycosides to have hypoglycemic effects that acted by 
increasing the release of insulin. These compounds also suppressed the transport of 
glucose from the stomach to the small intestine, and glucose transfer across the brush 
border of the small intestine.  
Other studies have helped to delineate the molecular mechanisms by which 
saponins regulate glucose metabolism and transport. Bhavsar et al. (2009b) treated 
diabetic and obese mice with saponins derived from the Helicteres isora plant and found 
a reduction in serum glucose and cholesterol levels. They also found changes in the gene 
expression of adipsin, Glut4, and PPARγ, genes regulating glucose and lipid transport 
and metabolism. In addition, Bhavsar et al. (2009a) identified changes in protein 
phosphorylation in C2C12 muscle cells as a result of treatment with saponins. They 
found that saponins activated the PI3k/Akt pathway to inhibit GSK-3β and stimulate 
glycogen synthesis. 
Astragaloside IV 
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 Given the evidence that saponins can activate the Akt pathway to improve glucose 
metabolism and transport, it strongly suggests that these glycosides can also activate this 
pathway to stimulate protein synthesis. While saponins have varying effects due to their 
structural variety, we will specifically be using Astragaloside IV (AsIV). AsIV is the 
main active component of the Astragalus membranaceus plant. This plant has been used 
in traditional Chinese medicine for many years for the treatment of cardiovascular disease 
and metabolic disorders (Ren et al. 2013), though it wasn’t until recently that AsIV was 
isolated from the plant in the lab and shown to be the compound providing these 
beneficial effects.  
 Studies have shown that AsIV exerts cardioprotective effects via inhibition of 
GSK-3β and activation of the Akt pathway. First, AsIV was shown to reduce cell death 
after ischemia/reperfusion injury to cardiac muscle cells via GSK-3β inhibition by 
preventing mitochondrial permeability transition pore opening (He et al. 2012). AsIV 
also decreased infarct size, mitochondrial swelling, and GSK-3β activity in an in vivo 
model of rat myocardial ischemia/reperfusion injury (He et al. 2014). Lastly, AsIV 
increased angiogenesis and cell migration in human epithelial cells subjected to hypoxia 
(Zheng et al. 2011). This effect was mediated by PI3K/Akt pathway activation. 
 AsIV also provides its effects on glucose metabolism and transport via activation 
of Akt. Du et al. (2018) used high-fat diet feeding in mice to induce adipose dysfunction, 
which led to increased endogenous hepatic glucose production and lipolysis. Subsequent 
AsIV treatment limited hepatic lipid accumulation and excess hepatic glucose production 
via Akt activation. In addition, Zhu et al. (2016) examined the effect of AsIV in a cellular 
model of insulin resistance. In C2C12 cells exposed to palmitate for 16 hours, AsIV 
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facilitated glucose uptake by increasing mRNA and protein levels of the GLUT4 glucose 
transporter, in turn reversing the effects created by palmitate. Again, this effect was 
mediated by phosphorylation and activation of the IRS/Akt pathway.  
 These studies consistently show that AsIV can activate Akt and inhibit GSK-3β 
via phosphorylation of the Akt pathway to provide downstream cardioprotective and 
glucose regulatory effects. We therefore hypothesize that AsIV activation of the IGF/Akt 
pathway in C2C12 muscle cells can also lead to downstream stimulation of protein 
synthesis.  
Materials and Methods 
Cell Culture 
 C2C12 cells (CRL-1772, American Type Culture Collection (ATCC), Rockville, 
MD), a murine drived skeletal muscle cell line, were grown in proliferation media (PM): 
Dulbecco’s Modified Eagle Medium (DMEM) (ATCC, Rockville, MD) supplemented 
with 10% fetal bovine serum and 1% Penicillin-Streptomycin (P/S) (10,000 U/ml, 
Thermo Fisher Scientific, Waltham, MA). As C2C12 cells exited the proliferatory phase 
upon confluency, cells were passaged at 70-80% confluence in order to expand cell 
populations. To perform experimental treatments, the cells were allowed to reach 100% 
confluency, after which the culture media was switched from PM to differentiation 
media: DMEM supplemented with 2% horse serum (Thermo Fisher Scientific, Waltham, 
MA) and 1% P/S to induce differentiation into contractile myotubes (Figure 3). Cells 
were then allowed to differentiate for four days prior to treatment. All cell cultures were 
incubated at 37° C and 5% CO2 at all times.  
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Figure 3: Representative image of cultured cells after differentiation. After reaching 100% confluence, cells 
were induced to differentiate for 4 days in DMEM supplemented with horse serum. This resulted in 
differentiation into contractile myotubes visible under light microscopy (see arrows). 
Reagents 
AsIV and Dexamethasone (Dexa) were obtained from Cayman Chemical 
Company (Ann Arbor, MI) in powdered form. AsIV was dissolved in dimethyl sulfoxide 
(DMSO) to create stock concentrations of 12.5 mM. Dexa was dissolved in DMSO and 
maintained in stocks of 10 mM and 100 mM. Long R3 IGF-1 (IGF1) (Millipore Sigma, 
St. Louis, MO) is a recombinant analog of the human IGF-1 and was diluted in H20 at 1 
mg/ml. All stock chemicals were stored at 4°C. 
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Antibodies 
Phosphorylation of AKT was determined with rabbit polyclonal anti-AKT (BD 
Biosciences, San Jose, CA) and mouse phospho-AKT (Ser473) (Cell Signaling 
Technologies, Danvers, MA). Phosphorylation of GSK-3β was determined using rabbit 
polyclonal anti-GSK-3β (BD Biosciences, San Jose, CA) and phospho-GSK-3β (Ser9) 
antibodies (Cell Signaling Technologies, Danvers, MA). Phosphorylation of S6K1 was 
determined using rabbit polyclonal anti-S6K1 (BD Biosciences, San Jose, CA) and 
phospho-S6K1 (Thr389) antibodies (Cell Signaling Technologies, Danvers, MA). 
IRDye® 800 CW Infrared Dye goat anti-mouse and IRDye® 680 CW Infrared Dye goat 
anti-rabbit secondary antibodies (LI-COR Biosciences, Lincoln, NE) were used for 
fluorescent quantification.  
Cell Treatment 
 Time-Course 
In order to determine the ideal treatment conditions, a time-course experiment 
was performed. Based on previous research, each plate was exposed to a vehicular 
control (DMSO) or 12.5 µM of AsIV. ). The 12.5 µM concentration of AsIV was chosen 
based on previous studies that have shown AKT activation in C2C12 myotubes using 
similar concentrations (Du et al. 2018; Zhu et al. 2016). Cells were treated for zero hours 
(control), 1, 2, 4, and 6 hours before harvesting the cells. Each time point was run in 
duplicate. The highest level of phosphorylation was found after two hours (Figure 4), so 
two hours was chosen as the optimal incubation time. 
Treatment 
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From the result of the time course, two hours was chosen as the optimal 
incubation time for all treatments in the study. For treatment groups, cells were grown to 
confluency in PM and switched to DM to induce myotube formation (Day 0). At Day 4, 
cells were treated with fresh DM with 0.2% DMSO (VC), 12.5 µM AsIV, 100 ng/ml 
IGF1 alone or in combination with 10 µM Dexa (Dexa alone, Dexa + AsIV or Dexa + 
IGF1). Groups treated with Dexa were treated 48 hours prior to harvest starting on Day 2 
to adequately inhibit Akt phosphorylation and protein synthesis prior to AsIV or IGF1 
treatment for two hours (Latres et al. 2005).  
Exposure to DMSO was normalized at 0.2% for all treatment groups. Each series 
of experiments was repeated twice using different passages of C2C12 myotubes (p6 and 
p7). Groups treated with IGF1 were also incubated for 2 hours to maintain consistency 
with the AsIV treatment time. The same concentration we used, 100 ng/ml, is capable of 
phosphorylating and activating mTOR in less than two hours (Miyazaki et al. 2010). 
Protein Isolation and Immunoblot Analysis 
After two hours of treatment, cells were lysed in a modified RIPA buffer 
containing 50 mM Tris-HCl, pH 7.4, 150mM NaCL, 1 mM EDTA, 25 mM NaF, 1 mM 
PMSF, 5 mM NaVO4, and 0.1% SDS. Protease Inhibitor Complex, Phosphatase Inhibitor 
Complex 2 and Phosphatase Inhibitor Complex 3 (Millipore/Sigma) were also added at 
10 µl/ml of buffer. Cell slurries were then centrifuged for 20 minutes at 20,000 x g at 4oC 
and the supernatants containing protein were removed to a fresh tube and stored at -80oC 
until use. Protein concentrations were quantified using Bradford Reagent (Thermo Fisher 
Scientific, Waltham, MA) according to manufacturer directions using a microplate reader 
(BioTek Instruments, Winooski, VT).  
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Westerns 
For immunoblot analysis, 20-30 µg of protein from the soluble fraction was 
denatured for ten minutes at 70° C in SDS loading buffer. The protein was then loaded 
onto a 4-15% NuPAGE BIS-TRIS protein gel (Invitrogen, Carlsbad, CA) and 
electrophoresed for 60 minutes at 200 V. After separation, proteins were transferred to an 
Immobilion-Fl PVDF membrane in a Transblot turbo for 30 minutes at 25V and 1 mA. 
Membranes were air-dried before continuing the blotting process. 
Membranes were re-wet with methanol, rinsed twice in DDH2O and stained using 
the ReVERT Total Protein Stain (LI-COR Biosciences, Lincoln, NE) according to 
manufacture protocol. Following the staining procedure, membranes were imaged using 
the 700 channel on an Odyssey CLx Infrared Imaging System (LI-COR Biosciences) and 
total lane protein was quantified to use for normalization of western blots according to 
manufacturer recommendations.  
 Following protein staining, membranes were rinsed and incubated in Odyssey 
Blocking Buffer (OBB)(LI-COR), for 1 hour. Blots were then incubated at 4oC overnight 
in primary antibody solution (OBB with 0.01% Tween) with primary antibody. 
Following primary incubation, membranes were washed 4 x 5 minutes in 1X TBS with 
0.01% tween (TBST). After washing, membranes were incubated with secondary 
antibody at 1:30,000 in OBB with 0.01% tween and 0.01% SDS for 1 hour. Membranes 
were washed 4 x 5 minutes in TBST, and then rinsed in 1X TBS to remove residual 
tween before air-drying. All membrane incubations were performed rocking at room 
temperature unless noted. Membranes were quantified on the Odyssey CLx and 
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normalized to the corresponding normalization factor, represented as relative signal units 
using Image Studio Software (LI-COR). 
Statistical Analysis 
 All data are expressed as means ± SD. Statistical significance for treatment 
groups was determined by using a two-way analysis of variance for multiple comparisons 
followed by a Tukey’s post hoc test. A P value of <0.05 was considered significant. 
Results 
AsIV optimally increases phosphorylation of Akt (S473), GSK-3β, and S6K1 after two 
hours of treatment  
 We first performed time course experiments to determine the optimal length of 
AsIV treatment for activation of the protein synthetic pathway. We found that Akt, GSK-
3β, and S6K1 had the highest levels of phosphorylation after 2 hours of treatment (Figure 
4). Compared to controls, there were 1.4, 1.6, and 4.4-fold increases in phosphorylation at 
the 2-hour time point for Akt (S473), GSK-3β, S6K1, respectively. These results suggest 
that two hours is the optimal length of time for AsIV treatment for the C2C12 
differentiated myotubes we are working with. Therefore, 2 hours of incubation time was 
used for all subsequent experiments. 
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Figure 4: Time course treatment of C2C12 cells with AsIV (n=2; DMSO control: n=2). All three target 
proteins showed the highest levels of phosphorylation after 2 hours of treatment. A. There was a 1.4 fold 
increase in Akt (S473) activation at 2 hours. B. There was a 1.6 fold increase in GSK-3β phosphorylation, 
indicating inhibition of GSK-3β. C. Lastly, there was a 4.4 fold increase in phosphorylation of S6K1.  
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AsIV does not affect target protein levels in serum-starved conditions 
 
 In order to further evaluate the effects of AsIV, cultures were placed in plain 
DMEM, starved of horse serum for 2 hours, then treated based on the group they 
belonged to as previously described (Miyazaki 2010). In theory, this should drop the 
level of baseline phosphorylation and we should therefore see a more pronounced 
stimulatory effect in our AsIV and IGF1 treatment groups. IGF1 showed significantly 
higher activation of Akt (P<0.001), and S6K1 (P=0.010) compared to controls. There 
was greater phosphorylation of GSK-3β as well, but this was not statistically significant. 
Treatment with AsIV, however, resulted in a non-significant decrease in phosphorylation 
of all target proteins, compared to controls (Figure 5).  
Cultures were then treated with Dexa for 48 hours to induce atrophy and inhibit 
the protein synthetic pathway. Cells were then incubated with either AsIV or IGF1 in an 
attempt to recover phosphorylation levels. AsIV was able to very modestly increase 
phosphorylation levels of both GSK-3β and S6K1, but did not increase Akt 
phosphorylation, compared to Dexa only cultures. IGF, on the other hand, was able to 
significantly stimulate phosphorylation of Akt (P<0.001) and S6K1 (P<0.001) even after 
Dexa treatment, as well as a non-significant increase in GSK-3β. These cultures 
recovered their phosphorylation levels and showed Akt pathway activation similar to the 
results found in cells only treated with IGF1.  
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Figure 5: Cells treated in serum-starved conditions (n=3). There was a decrease in phosphorylation of all 
target proteins when subjected to AsIV, compared to controls. In comparison, IGF was still able to induce 
phosphorylation in these conditions. However, after cells were treated with Dexa, AsIV was able to 
modestly increase phosphorylation levels of both GSK-3β (B) and S6K1 (C), but did not noticeably 
increase Akt (A) phosphorylation. IGF was able to recover activation after Dexa treatment in all targets, to 
levels similar to cells not initially treated with Dexa. 
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AsIV may affect target protein phosphorylation levels after initial treatment with 
dexamethasone 
 In light of the results we obtained with serum-starved trials, we repeated the 
experiments using cultures maintained in DMEM and 2% horse serum at all times prior to 
harvest (Figure 6). As a result, we found very modest increases in Akt and GSK-3β 
phosphorylation compared to controls, which were not statistically significant. However, 
this effect was not seen in S6K1, which had no change in phosphorylation levels when 
compared to controls. IGF1 was again able to consistently increase phosphorylation, 
especially in Akt (P=0.039) and S6K1 (P=0.038), with only modest increases in GSK-3β.  
 Cells were then incubated with Dexa for 48 hours prior to AsIV/IGF treatment. 
There was no difference in Akt phosphorylation after AsIV treatment, but considerable 
increases after IGF that approached significance (P=0.067). Phosphorylation of GSK-3β 
was also greatly increased in the Dexa + AsIV group (P=0.021) compared to cells only 
treated with Dexa. This was the only group in which AsIV was able to stimulate 
phosphorylation in a target protein to levels nearly as high as IGF. Lastly, phosphorylation 
of S6K1 was mildly increased in the Dexa + AsIV group, but significantly increased in the 
Dexa + IGF group (P<0.001). In no AsIV treatment group was phosphorylation levels 
higher than those seen with IGF. 
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Figure 6. Cells treated in the presence of Horse Serum (n=3). Cells were maintained in horse serum during 
the entirety of treatment. This resulted in greater increases in both Akt and GSK-3β after AsIV treatment 
compared to controls. However, it appeared that S6K1 did not increase at the same rate. In addition, the 
downstream targets of GSK-3β and S6K1 were able to recover phosphorylation levels after treatment with 
Dexa, especially with GSK-3β. 
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Discussion 
 Skeletal muscle atrophy can occur as a result of aging, lack of physical activity, or 
as a debilitating component of many diseases. One potential strategy for combating 
muscle loss is by stimulating the cellular pathways responsible for protein synthesis. It 
has been shown that the Akt/mTOR signaling pathway is the mechanism controlling the 
balance between protein synthesis and degradation. Therefore, it is important to find 
substances with the potential to activate this signaling pathway to promote protein 
synthesis. One such compound is Astragaloside IV, a saponin phytochemical commonly 
found in Astragalus membranaceus, used in traditional Chinese medicine for glucose 
homeostasis. Because this saponin is capable of activating the Akt pathway to stimulate 
glucose metabolism and transport, our hypothesis is that it can also stimulate downstream 
activation of the protein synthetic pathway as well. 
 In the current study, we first looked to determine what length of AsIV treatment 
time would lead to the highest increases in Akt pathway phosphorylation, if any. We 
found the highest levels of phosphorylation after two hours of treatment for Akt, GSK-
3β, and S6K1. These results suggest that two hours of treatment is optimal for Akt 
pathway activation in C2C12 muscle cells, so cultures were treated with AsIV for two 
hours in all subsequent experiments. 
 After two hours of treatment, phosphorylation generally declined in all target 
proteins. It is possible that is a result of the negative feedback loop between S6K1 and 
IRS. At sufficient quantities, activated S6K1 can act as an inhibitor of IRS by 
phosphorylating it at S270 (Zhang et al. 2008). This impairs the ability of the IRS to 
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stimulate glucose uptake and initiate protein synthesis. This could explain the decline we 
saw after two hours.  
 We then evaluated the effect of AsIV on myotubes subjected to serum-starved 
conditions two hours prior to treatment. There should theoretically be a decrease in basal 
protein synthesis activity in the absence of serum, which would lower the relative levels 
of Akt pathway activation. Subsequent treatment with AsIV or IGF would then provide 
an even more pronounced effect. Following serum starvation, we saw an increase in 
phosphorylation levels after IGF1 treatment alone and IGF1 treatment after Dexa pre-
treatment. However, this was not the case for AsIV. We actually found decreases in 
phosphorylation along the Akt pathway compared to controls. When cells were treated 
with Dexa for 48 hours prior to AsIV treatment, there was a mild increase in 
phosphorylation. This effect was most pronounced with GSK-3β. 
 IGF was able to stimulate the Akt pathway to similar levels whether cultures were 
subjected to Dexa first or not. It was interesting to see the large effect that IGF was 
capable of producing in serum-starved conditions, compared to the decreases seen in 
AsIV cultures. Our hypothesis is that IGF is such a potent activator of the Akt pathway 
that the composition of the media does not make a considerable difference. It appears that 
IGF is still capable of activation in the absence of the growth factors provided by horse 
serum. Horse serum provides cells with growth factors, proteins, and trace elements for 
optimal growth and differentiation into myotubes. Although the absence of serum may 
drop baseline levels of Akt activation, it may also promote cell death due to the lack of 
essential elements for growth (Leicht et al. 2003; Simm et al. 1997). It is possible that 
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AsIV requires the presence of these growth factors and trace elements to enhance Akt 
pathway activation rather than activate from baseline levels.  
 We then repeated our experiments with horse serum continuously present until the 
cells were ready to harvest. Although we found modest increases in phosphorylation for 
Akt and GSK-3β after AsIV treatment, we found no increase in S6K1. This results is 
contradictory to the results seen in the time course experiments that showed over 4 times 
greater phosphorylation after 2 hours of AsIV treatment (See Figure 4). The one change 
in procedure between the two experiments was that the time course was performed in 100 
mm culture plates, whereas the experimental groups thereafter were cultured in 60 mm 
plates. However, this should not cause such a change by itself. Similar to the serum-
starved cultures, GSK-3β and S6K1 phosphorylation rose with AsIV treatment after 
initial incubation with Dexa for 48 hours. This effect was again most pronounced with 
GSK-3β, where Dexa + AsIV phosphorylation was nearly has high as IGF + Dexa. 
 It was interesting to see the profound increases in GSK-3β for the Dexa + AsIV 
group, the only trial that was comparable to IGF levels (See Figure 6). This may be 
related to role that GSK-3β also plays in cell survival and apoptosis. Although originally 
named for its role in glycogen metabolism, GSK-3β has since been shown to play roles in 
protein synthesis, cell proliferation, and cell division (Frame and Cohen 2001). 
Paradoxically, GSK-3β appears to play a role in cell death and cell survival. GSK-3β 
inhibition via PI3K can prevent cell death (Pap and Cooper 1998) and mice with a 
homozygous deletion of GSK-3β died before birth due to apoptotic liver degeneration 
(Hoeflich et al. 2000).  
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As discussed previously, AsIV can provide cardioprotective effects through Akt/GSK-3β 
phosphorylation. Through inhibition of GSK-3β, AsIV is capable of reducing cell death 
after ischemia/reperfusion injury to cardiac muscle cells in vitro (He et al. 2012) and 
minimizing cell damage in vivo (He et al. 2014). It is possible that Dexa, in addition to 
inhibition of protein synthesis, also led to some cell death. This may have been enough to 
stimulate AsIV to exert cell survival effects in muscle cells via GSK-3β inhibition.
 It is entirely possible that AsIV can activate the Akt/GSK-3β pathway without 
subsequent protein synthesis activation. A recent study looked to determine if AsIV could 
protect retinal ganglion cells from oxidative injury (Hao et al. 2018). They found that 
AsIV reduced the level of reactive oxygen species (ROS) and mitigated ROS-induced 
changes to the mitochondria. This recent evidence is important for our study because 
ROS are extremely important for IGF1-induced hypertrophy in C2C12 muscle cells in 
vitro (Handayaningsih et al. 2011). IGF1 induced ROS production in C2C12 myocytes, 
and treatment with additional H2O2 enhanced IGF1-induced phosphorylation of the 
IGFR. This increase in phosphorylation was inhibited by the addition of antioxidants. 
Future studies should assess for ROS levels in AsIV-treated muscle cells, as these 
antioxidant properties may be suppressing protein synthesis and growth.  
 Future studies should continue to determine how AsIV affects skeletal muscles 
cells, especially in the context of protein synthesis. We hope to evaluate the downstream 
effects of Akt activation by measuring myotubes sizes before and after treatment, as well 
as using the SUnSET method to quantify the rate of protein synthesis.  SUnSET (SUrface 
SEnsing of Translation) utilizes puromycin-labeled peptides and anti-puromycin 
antibodies to quantify the rate of protein synthesis between cell cultures via 
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immunodetection (Schmidt et al., 2009). Given the role that GSK-3β plays in cell 
apoptosis, it would also be interesting to track cell survival as a result of AsIV treatment.  
 Protein homeostasis is a constant balance between protein synthesis and 
degradation. Both are present, even in the presence of muscle growth. There is increases 
in both synthesis and degradation, but a comparatively greater increase in synthesis when 
there is growth. Conversly, in the presence of atrophy there will be increases in both 
again, but a greater rate of degradation than synthesis. In addition to markers of protein 
synthesis, further studies should therefore evaluate the effect of AsIV on markers of 
protein degradation.  
IGF-1 has been shown to be sufficiently capable of stimulating protein synthesis 
on its own (DeVol et al. 1990), and the results of our study appear to confirm this. 
Although there is promise for IGF-1 to treat muscle wasting itself, IGF-1 receptors are 
ubiquitously expressed all over the body so any form of systemic treatment may affect 
other tissues as well (Gross 2003). It would interesting to see if AsIV can augment the 
effects of IGF-1, if muscle cells were treated with both concurrently. 
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